With the recent explosion in popularity of the GLP-1 agonist medications for obesity, Dr. Nally discusses a little known problem (muscle loss) becoming more significant with these drugs popularity. 
If you've ever considered using any of these medications in this class, you'll want to tune in to this podcast. 
#GLP1 #semaglutide #dulalutide #tirzepatide #liraglutide #exanatide #sarcopenia #Diet #Food #FoodIsMedicine #LeadFolloworGetOutOrMyWay #JustKeepEsterifying #Ketogenic #Keto #KetogenicLifestyle #Carnivore #DrAdamNally #DocMuscles #DocMusclesLive #DocTalk #DocsWhoLift #LiftRunShoot #DocMusclesLife #PlantBasedDietsSuck #Muscles #Cytokines #incretin #NoBSsm #Exercise
References:

Wilding JPH, et al. STEP 1 Study Group of the Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021; 384:989-1002.  DOI: 10.1056/NEJMoa2032183.
McCrimmon, R.J., Catarig, AM., Frias, J.P. et al. Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial. Diabetologia 63, 473–485 (2020). https://doi.org/10.1007/s00125-019-05065-8